Recall archive / FDA drug enforcement
Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc. North Chicago, I... — FDA record D-0088-2024
Reported ongoing
Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.
Source date Oct 17, 2023. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- Synthroid, Levothyroxine Sodium Tablets, USP 125mcg (0.125mg), 100-count bottle, Rx Only AbbVie Inc. North Chicago, IL 60064, U.S.A. NDC 0074-7068-11
- Reason
- Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.
- Classification
- Class III
- Recalling firm
- AbbVie Inc.
- Quantity
- 864 cartons
- Agency-reported status
- Ongoing
- Source record identifier
- D-0088-2024
What the recall classes mean. Classification is an agency assessment, not individual medical advice.
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | Lot # 1187435 exp date: 02/2024 |
Match all identifying details in the current notice. A brand name alone is not enough.
Distribution
Distributed in the US. No government or foreign consignees.
No US distribution state could be established from this record. Check the official notice.
Dates in the source
- Report date
- Nov 15, 2023
- Recall initiation date
- Oct 17, 2023
- Center classification date
- Nov 5, 2023
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.